Former NIH Leaders Allege Retaliation for Whistleblowing
Briefly

Former NIH Leaders Allege Retaliation for Whistleblowing
"Jeanne Marrazzo, former director of the National Institute of Allergy and Infectious Diseases, and Kathleen Neuzil, former director of the NIH's Fogarty International Center and former associate director for international research, filed complaints Thursday with the U.S. Office of Special Counsel, seeking reinstatement. They allege they faced retaliation for whistleblowing and other protected activity. Marrazzo "objected to the Administration's hostility towards vaccines and its abrupt cancellation of grants and clinical trials for political reasons," according to her complaint."
"Neuzil further objected to the administration's "cancellation of grants based on anti-South Africa hostility and its incorrect belief that certain grants advanced 'diversity, equity, and inclusion,'" her complaint stated. They both specifically allege that Matthew Memoli-who was NIH's acting director after Trump returned to power and is now NIH's principal deputy director-retaliated against them. An NIH spokesperson said in an email Friday that Memoli emphasizes that each vaccine "must be assessed on its own merits.""
Two former NIH leaders say the agency illegally placed them on leave in April after they spoke up against research grant cancellations and antivaccine efforts. Jeanne Marrazzo and Kathleen Neuzil filed complaints with the U.S. Office of Special Counsel seeking reinstatement and alleging retaliation for whistleblowing and other protected activity. Marrazzo objected to the administration's hostility toward vaccines and the abrupt cancellation of grants and clinical trials for political reasons. Neuzil objected to cancellations tied to anti–South Africa hostility and to claims that certain grants advanced 'diversity, equity, and inclusion.' Both allege retaliation by Matthew Memoli. NIH responded that vaccines must be assessed on their merits and that accusations of 'anti‑science' cancellations misrepresent NIH progress.
[
|
]